Table 3.
Associations of hotspot mutations related to HCC risks stratified by HBV genotypes
| Hotspot mutation | CHB (%) | LC (%) | HCC (%) | HCC versus. HBV-infected subjects without HCC | |
|---|---|---|---|---|---|
| AORa (95% CI) | P value | ||||
| In genotype B HBV-infected subjects | |||||
| T1753A/C | 6.12 (6/98) | 15.00 (12/80) | 8.14 (14/172) | 0.57 (0.27–1.20) | 0.139 |
| A1762T/G1764A | 34.69 (34/98) | 37.50 (30/80) | 60.47 (104/172) | 1.88 (1.19–2.98) | 0.007 |
| A1846T | 16.33 (16/98) | 15.00 (12/80) | 36.05 (62/172) | 2.00 (1.16–3.45) | 0.013 |
| G1896A | 16.33 (16/98) | 20.00 (16/80) | 43.02 (74/172) | 2.31 (1.36–3.93) | 0.002 |
| In genotype C HBV-infected subjects | |||||
| C1653T | 14.56 (46/316) | 19.75 (64/324) | 22.86 (198/866) | 1.55 (1.17–2.04) | 0.002 |
| T1674C/G | 15.82 (50/316) | 14.81 (48/324) | 24.25 (210/866) | 1.83 (1.38–2.44) | 3.35 × 10 − 5 |
| T1753A/C | 14.56 (46/316) | 13.58 (44/324) | 21.94 (190/866) | 1.89 (1.40–2.53) | 2.47 × 10 − 5 |
| A1762T/G1764A | 42.41 (134/316) | 46.91 (152/324) | 60.97 (528/866) | 2.09 (1.51–2.91) | 1.13 × 10 − 5 |
| G1719T | 36.08 (114/316) | 39.51 (128/324) | 44.57 (386/866) | 1.39 (1.06–1.83) | 0.017 |
| A1846T | 15.82 (50/316) | 14.81 (48/324) | 19.63 (170/866) | 1.53 (1.14–2.06) | 0.005 |
| G1896A | 27.85 (88/316) | 15.43 (50/324) | 30.25 (262/866) | 1.93 (1.47–2.54) | 2.60 × 10 − 6 |
| G1899A | 5.06 (16/316) | 8.02 (26/324) | 15.47 (134/866) | 2.96 (2.03–4.32) | 1.77 × 10 − 8 |
| preS deletion | 12.66 (40/316) | 18.52 (60/324) | 19.63 (170/866) | 1.77 (1.32–2.39) | 1.53 × 10 − 4 |
a AOR, odds ratio adjusted for age, gender, HBeAg, HBV DNA load, ALT, and AST in the comparison between HCC and HBV-infected subjects with HCC.
HBV hepatitis B virus, CHB chronic hepatitis B, LC liver cirrhosis, HCC hepatocellular carcinoma